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Graphical abstract
Highlights
• Plasma PRO-C3 levels correlate with severity of stea-
tohepatitis and fibrosis stage.
• FIBC3 panel achieves good sensitivity and specificity
for the identification of F≥3 fibrosis in NAFLD.
• FIBC3 panel uses a single threshold value, eliminat-
ing indeterminate results and outperforming other
non-invasive tools.
• A simplified version (ABC3D) is readily amenable to
use in clinical practice.
https://doi.org/10.1016/j.jhepr.2019.06.004
Lay summary
We performed a comprehensive, independent evalua-
tion of a collagen biomarker (PRO-C3) to detect and
quantify liver fibrosis in patients with non-alcoholic
fatty liver disease (NAFLD). We report the develop-
ment of 2 diagnostic panels using PRO-C3 to identify
patients with advanced fibrosis, one optimal but more
complex to calculate (FIBC3), the other easier to use
(ABC3D) whilst still performing well.
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Background & Aim: There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can
diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct
marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and
report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a
simplified clinical score which eliminates the need for online calculators.
Methods: Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy
diagnosed NAFLD across the full disease spectrum (F0: n = 90; F1: 100; F2: 92; F3: 101; F4: 66). The cohort was divided into a dis-
covery group (n = 151) and a validation group (n = 298). Logistic regression was performed to establish complex (FIBC3) and sim-
plified (ABC3D) diagnostic scores that accurately identify advanced fibrosis. Performance for each was compared to established
non-invasive fibrosis scoring systems.
Results: Plasma PRO-C3 levels correlatedwith grade of histological steatohepatitis (rs = 0.367, p <0.0001) and stage of fibrosis (rs =
0.462, p <0.0001), exhibiting similar performance to current fibrosis scores such as FIB4 for the detection of F≥3 fibrosis. FIBC3
exhibited substantially improved accuracy (AUROC 0.89 and 0.83 in the discovery and validation sets, respectively) and outper-
formed FIB4 and other similar diagnostic panels. The simplified version, ABC3D, was concurrently developed and had comparable
diagnostic accuracy (AUROC 0.88 and 0.81 in the discovery and validation sets, respectively).
Conclusion: Plasma PRO-C3 levels correlatewith severity of steatohepatitis and fibrosis stage. The FIBC3 panel is an accurate tool
with a single threshold value that maintains both sensitivity and specificity for the identification of F≥3 fibrosis in NAFLD, elimi-
nating indeterminate results and outperforming commonly used non-invasive tools. A greatly simplified version (ABC3D) that
is readily amenable to use in the clinic has been validated and shown to perform with similar accuracy, and may prove a useful
tool in routine clinical practice.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) represents a continuum of
liver injury, ranging from steatosis affecting >5% of hepatocytes, to
fatty liver in the presence of inflammation and hepatocyte balloon-
ing (non-alcoholic steatohepatitis [NASH]), with or without fibrosis,
through to cirrhosis.1 Fibrosis has emerged as the key histological
determinant of long-term prognosis.2–5 Liver biopsy is generally
viewed as an imperfect reference standard for grading diseaseKeywords: NAFLD; NASH; Steatohepatitis; fibrosis; PRO-C3; Biomarker.
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given the magnitude of the “at risk” population.6–8 Therefore, the
increasing prevalence of NAFLD necessitates a shift from histology
towards the development of non-invasive assessments. This chal-
lenge not only impacts routine clinical management but also the
clinical investigation of potential new therapies to prevent the pro-
gression of fibrotic NASH to cirrhosis. The current regulatory path-
way to registration requires demonstration of improvement in
histological features of NASH.9 Consequently, a significant major-
ity of the potential participants in recent clinical trials in NASH
have been requested to undergo liver biopsy as part of the screen-
ing process. Biopsy is not without burdens and risks for patients,
investigator sites and study sponsors. Rates of screening failure
of up to 70% have been reported after biopsy.10 Hence, minimally
invasive techniques are sought to identify study participants with
the highest probability of demonstrating qualifying histological
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Fig. 1. Patient flow for analysis inclusion.features on biopsy. The current study addresses the performance
of the PRO-C3 biomarker within the FDA BEST (Biomarkers,
EndpointS and other Tools) defined diagnostic context of use.11
Blood-based non-invasive tests for fibrosis can be dichotomised
into “indirect makers”, including simple non-invasive fibrosis
scores derived from clinical and biochemical indices, such as the
fibrosis-4 (FIB4) score and the NAFLD fibrosis score (NFS),12–16
and “direct biomarkers” thatmeasure collagen deposition ormatrix
turnover.17,18 Themajority of non-invasive tests exhibit high nega-
tive predictive value, implying that they are best employed to
exclude patients without advanced fibrosis (Kleiner ≤F2). However,
many issues existwith currently available biomarkers. For example,
FIB4 and NFS provide “indeterminate” results in a quarter of
patients19 and although elastography based techniques such as
Fibroscan™ (vibration controlled transient elastography [VCTE])
have a competitive diagnostic accuracy, they require specialist
equipment, are operator dependent and exhibit low success rates
in obese patients.20 Magnetic resonance elastography can accu-
rately diagnose fibrosis in patients with NAFLD.21,22 However, it is
expensive and not widely available in most centres. A mandate
therefore exists for improved biomarkers.
Research exploiting knowledge of collagen structure and
protease-protein interactions have resulted in the design of a spe-
cific ELISA that measures ADAMS2 mediated collagen cleavage
during the formation of type III collagen in fibrogenesis.23,24 Pre-
vious studies have shown that measuring formation of type III
collagen neo-epitopes (PRO-C3) as a single diagnostic marker or
by incorporation into a diagnostic panel can provide a reasonably
accurate assessment of disease stage and activity, but to date the
diagnostic panels require complex mathematical calculations
necessitating the use of an online App.25–30 Similarly, NFS and
FIB4 require the use of online calculators to generate a result.
This may be onerous in a busy clinical environment, limiting
adoption in the primary care setting.31,32 A simplified but accurate
fibrosis assessment algorithm would therefore help physicians to
risk stratify patients without recourse to an online calculator.
In the current study, we seek to: i) assess the performance of
PRO-C3 as a NASH-fibrosis biomarker within the BEST diagnostic
context of use; ii) develop and validate a novel biomarker panel
incorporating PRO-C3 and determine its performance in compari-
son to established clinical scores and previously reported biomar-
ker panels; and iii) develop and validate a simplified clinical tool
that is both accurate and clinically accessible immediately.
Materials and methods
Study design and participants
Fig. 1 shows the flow of patients through the study. Participants
were recruited at 7 specialist European centres. Patients eligible
for inclusion were ≥18 years, with suspected NAFLD undergoing a
diagnostic liver biopsy on clinical grounds. Patients were excluded
if they had evidence of coexistent liver disease or consumed greater
than 30 g of alcohol per day for males or greater than 20 g per day
for females. The human biological samples were sourced ethically
following receipt of informed consent from each patient and their
research usewas in accordancewith the terms of the informed con-
sents under an IRB/EC approved protocol at participating centres.
Clinical and laboratory assessments
Gender, age and body mass index (BMI; weight (kg)/height (m2))
were recorded for all patients at time of index liver biopsy. Patients
were classified as having type 2 diabetesmellitus (T2DM) if HbA1cJHEP Reports 2019was >6.5% or theywere receiving dietary, oral hypoglycaemic drug
or insulin treatment for T2DM. Blood tests taken at the time of liver
biopsy were used to calculate the simple non-invasive scores. The
FIB4 score, APRI (aspartate aminotransferase to platelet ratio
index), NFS, ADAPT (Age, Diabetes, PRO-C3 and platelets panel)
score and BARD (BMI, aspartate aminotransferase to alanine
aminotransferase ratio [AAR], T2DM) score were calculated and
applied as previously described.13,29,33–35 PRO-C3 and additional
biomarkers PRO-C6, PRO-C4, C4M were assessed using competi-
tive ELISAs (Nordic Bioscience A/S, Denmark) measured by ex-
perienced technicians unaware of any associated clinical data.23,36
Histological assessment
Liver biopsies were performed at each centre as per unit protocol.
Target biopsy length was ≥15 mm. Biopsies were stained with
haematoxylin and eosin andMasson's trichrome.Histological diag-
nosis, grade of steatosis and scoring for NAFLD activity and fibrosis
stage were performed by expert liver pathologists at each study
site according to the NASH Clinical Research Network (CRN) classi-
fication.37 To reduce the element of inter-observer variability, over
half of all biopsies (254, 57%) in our study were centrally reviewed
by an expert member of the Elucidating Pathways of Steatohepati-
tis (EPoS)HistopathologyGroup (DT). Aweighted kappa coefficient
of 0.90 for fibrosis stage was established, demonstrating a very
high level of inter-observer agreement.
Statistical analysis
The primary endpoint of the study was to predict the presence of
advanced fibrosis (stages 3–4). The combined cohort of 449patients
was randomly separated into approximately 1/3 (n = 151) (dis-
covery cohort) and 2/3 (n = 298) of patients (validation cohort)
for model building and validation. Continuous variables were
compared using the t test and categorical variables using Fisher’s
exact test. The Kruskal-Wallis test was used to perform compari-
sons between mean marker levels followed by Dunn’s multiple
comparison tests. In the discovery cohort, significant variables
on univariate analysis (p <0.05) were included in the backwardvol. 1 | 188–198 189
Research Articlestepwisemultiple logistic regression analysis to identify indepen-
dent factors associated with fibrosis. Variables with p <0.05 by
multivariate analysis were used to construct scoring systems
(FIBC3 and ABC3D) to predict advanced fibrosis. Optimal cut-offs
for each component of ABC3D were selected using the Youden
index (J-Index) which attributes equal value to sensitivity and
specify. Cross-validation was performed using the leave-one-out
method to facilitate the calculation of over-fit bias reduced
estimates. We calculated reduced bias estimates of predicted
probability. This involved removing each individual subject and
re-estimating the model parameters and then classifying the sub-
ject based on the newparameters. This enabled us to interrogate a
suspicious positive or negative validation subject.
The diagnostic accuracies of both scoring systems were
determined by calculating the area under the receiver operating
characteristic curve (AUROC, the c-statistic) and its 95% CIs. The
5-point fibrosis scales presented both spectrum effect and ordinal
scale issues. To overcome this, we calculated the Obuchowski
measure using the package “nonbinROC” version 1.0.1 (https://
CRAN.R-project.org/package=nonbinROC) using the R statistical
analysis software platform.38 This is a measure of the probabilityTable 1. Baseline demographic and clinical characteristics of participants.^
Variable All patients
(n = 449)
Discover
Age (years) 52 ± 13
Gender (male) 263 (59%)
BMI (Kg/m2) 32.6 ± 6.8
T2DM 216 (48%)
ALT (U/L) 69 ± 41
High ALT (>40 U/L) 340 (76%)
AST (U/L) 47 ± 26
Albumin (g/dl) 44 ± 5
Platelets (X109/L) 230 ± 72
Cholesterol (mg/dl) 7 ± 14
Triglycerides (mg/dl) 3.8 ± 17
Collagen PRO–C3 (ng/ml) 18.9 ± 15
Collagen PRO–C6 (ng/ml) 9.6 ± 4.4
PRO–C4 (ng/ml) 266 ± 142
C4M (ng/ml) 27.3 ± 10
C3M (ng/ml) 11.6 ± 4
Fibrosis Stage (0/1/2/3/4) 90/100/92/101/66
Steatosis (0/1/2/3) 10/149/171/110
Ballooning (0/1/2) 112/188/138
Lobular Inflammation (0/1/2/3) 48/219/147/24
NAS 4 ± 2
FIB4 1.53 ± 1.07
AAR 0.76 ± 0.31
NAFLD Fibrosis Score –1.304 ± 1.796
APRI 0.68 ± 0.48
ADAPT Score 6.3 ± 2.2
BARD Score 2 ± 1
Centrally reviewed biopsies 254 (57%)
Mann-Whitney/ t tests were used to test for significant differences within continuous var
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T
^The table shows the mean ± SD for continuous variables, number (%) for binary variable
JHEP Reports 2019that our fibrosis index will correctly rank 2 randomly chosen
patient samples from different fibrosis stages according to
the weighting scheme, with a penalty score of 1 for incorrect
scoring.39 The method of DeLong, DeLong and Clarke-Pearson
was used to compare AUROCs.40 Validation was performed in
(1) the validation dataset (n = 298) and (2) in the full dataset
(n = 449). Using the ROC curve for the final model, a cut-off
point was selected using the Youden index (J-Index). ROC curves
were also calculated for the established diagnostic scores, AAR,
FIB4, APRI, NFS, BARD and the recently described ADAPT
score.10,24,27–29 All statistical analyses were performed using
SPSS software version 24.0 (SPSS Inc, Chicago, USA), R and SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of patient population
Table 1 summarises the clinico-demographic details of the study
population. The 449 patients were pooled from 7 international
centres (Table S1). No country of origin/centre effect was
detected in the analysis (p = 1.000).y cohort (n = 151) Validation group (n = 298) p value
51.6 ± 13 51.5 ± 13 0.957
94 (62%) 169 (57%) 0.260
32.9 ± 7.1 32.4 ± 6.4 0.608
74 (49%) 142 (48%) 0.786
66 ± 39 71 ± 42 0.166
112 (74%) 228 (77%) 0.585
47 ± 26 48 ± 26 0.339
44 ± 4 44 ± 5 0.780
225 ± 61 233 ± 77 0.448
7 ± 10 7.1 ± 16 0.630
3.6 ± 16 3.9 ± 18 0.758
18.1 ± 14 19.3 ± 15 0.438
9.3 ± 4 9.8 ± 4.7 0.501
253 ± 147 273 ± 139 0.067
26.8 ± 10.1 27.6 ± 9.8 0.374
11.6 ± 4.8 11.6 ± 4.2 0.644
36/28/27/34/26 54/72/65/67/40 0.309
6/50/56/35 4/99/115/75 0.342
38/60/49 74/128/89 0.791
18/78/43/8 30/141/104/16 0.578
4 ± 2 4 ± 2 0.848
1.55 ± 1.08 1.52 ± 1.06 0.483
0.79 ± 0.34 0.75 ± 0.30 0.428
–1.182 ± 1.797 –1.367 ± 1.795 0.303
0.68 ± 0.51 0.68 ± 0.46 0.718
6.3 ± 2.3 6.4 ± 2.2 0.652
2 ± 1 2 ± 1 0.428
79 (52%) 175 (59%) 0.622
iables and Chi-Square test was used for categorical variables.
2DM, type 2 diabetes mellitus.
s, and number per group for categorical variables.
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Fig. 2. PRO-C3 and its association with non-alcoholic fatty liver disease severity (complete cohort n = 449). Spearman’s correlation coefficient rs measures the
strength and direction of association between 2 variables. Independent samples were compared using the Kruskal-Wallis test. All data are represented as medians,
with variation in expression shown in Tukey plots. P values <0.05 were considered significant.PRO-C3 levels correlated with steatohepatitis and fibrosis stage
Across all histological features (steatosis, lobular inflammation,
hepatocyte ballooning, fibrosis), PRO-C3 was positively asso-
ciated with increasing NAFLD severity (Fig. 2). In the discovery
cohort (n = 151), PRO-C3 correlated with the NAFLD activity
score (NAS) (rho = 0.304, p <0.0001) and fibrosis stage (rho =
0.422, p <0.0001). Confirming that PRO-C3 is primarily a fibrosis
marker, the correlation with fibrosis stage remained significant
when controlling for NAS however the converse did not hold
true. Indeed, PRO-C3 exhibited the strongest correlation with
fibrosis stage when compared to a number of other putative
extracellular matrix turnover biomarkers (PRO-C6 (rho = 0.355),
PRO-C4 (rho = 0.279), C4M (rho = 0.177), p <0.05).
In the discovery cohort (n = 151) an optimal PRO-C3 cut-off
level for the detection of advanced fibrosis was determined.
PRO-C3 >15.5 ng/ml had an AUROC of 0.73 for the detection ofTable 2. Variables Associated with the Presence of Advanced Fibrosis (stage F3-
Univariate
Variable Odds Ratio 95% CI p
Age 1.088 1.049–1.128 <0
Gender 1.172 0.599–2.291
BMI 1.090 1.035–1.148
T2DM 8.570 4.003–18.348 <0
ALT 1.002 0.994–1.011
AST 1.020 1.005–1.034
Albumin 0.934 0.853–1.021
Platelets 0.986 0.986–0.979 <0
Cholesterol 0.841 0.714–0.990
Triglycerides 1.024 0.952–1.101
PRO-C3 1.079 1.039–1.120 <0
AST-ALT Ratio 3.072 1.119–8.436
FIBC3:
–5.939 + (0.053*Age) + (0.076*BMI) + (1.614*T2DM) – (0.009*platelets) + (0.071*P
ABC3D:
Age >50 = 1 point, BMI >30 = 1 point, platelet Count <200 = 1 point, PRO–C3 >15
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; T
JHEP Reports 2019advanced fibrosis ≥F3 (sensitivity 60%, specificity 74%, accuracy
68%). This was replicated in the validation cohort (n = 298)
(AUROC = 0.78, sensitivity 72%, specificity 71%, accuracy 71%)
(Table S2). The sensitivity and specificity for fibrosis across a
range of PRO-C3 thresholds are reported for the overall cohort
(Table S3).
Development of panels incorporating PRO-C3 that are
diagnostic for advanced fibrosis
To identify other clinical factors that readily predict the presence of
fibrosis, additional analyses were conducted. Table 2 shows the
results of univariate and multivariate analyses preformed in the
discovery cohort. Using backward logistic regression, 5 variables
remained significantly associated with advanced fibrosis: age,
BMI, T2DM, platelets and PRO-C3. Nomulti-collinearitywas identi-
fied between variables used in the model. Variables were assessed4) in the Discovery Cohort (n = 151).
Adjusted (Multivariate)
value Odds Ratio 95% CI p value
.0001 1.055 1.008–1.103 0.022
0.643
0.001 1.079 1.014–1.148 0.017
.0001 5.023 1.920–13.140 0.001
0.611
0.007
0.133
.0001 0.991 0.982–1.000 0.039
0.038
0.520
.0001 1.074 1.023–1.127 0.004
0.029
RO–C3)
.5 = 1 point, Diabetes = 2 points
2DM, type 2 diabetes mellitus.
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Research Articlefor all 2-way interactions with no significant outcomes (p >0.05).
These 5 variables were incorporated into a model that distin-
guished advanced fibrosis (F3-4) from mild fibrosis (F0-F2). The
diagnostic panel “FIBC3” was calculated from the regression for-
mula for prediction of severity of fibrosis: -5.939 + (0.053*Age) +
(0.076*BMI) + (1.614*T2DM) – (0.009*platelets) + (0.071*PRO-C3).
FIBC3 correlated strongly with fibrosis stage (rho = 0.630,
p <0.0001), which remained significant independently of NAS. In
the discovery cohort, the AUROC for FIBC3 was 0.89 (95% CI
0.843–0.941, p <0.001).
To facilitate adoption in a clinical setting, a simplified score
based on the same 5 variables identified as significant on univariate
analysis andweighted according to their odds ratio (OR) valueswas
generated. The derived “ABC3D” score comprises:A =Age>50 years,
B = BMI>30, C = platelet Count<200, 3 = PRO-C3>15.5 ng/ml,Table 3. Diagnostic accuracy of non-invasive tests by detecting Histologic stage
Non-invasive test AUROC 95% CI
AAR 0.67 0.615–0.716
APRI 0.75 0.698–0.794
BARD 0.71 0.664–0.761
FIB4 0.78 0.732–0.820
NFS 0.79 0.751–0.838
ADAPT 0.85 0.815–0.888
PRO–C3 0.76 0.718–0.811
FIB–C3 0.85 0.812–0.886
ABC3D 0.83 0.793–0.868
p value <0.0001
AAR 0.66 0.579–0.751
APRI 0.75 0.669–0.830
BARD 0.76 0.683–0.834
FIB4 0.80 0.726–0.867
NFS 0.85 0.791–0.911
ADAPT 0.86 0.800–0.917
PRO–C3 0.75 0.661–0.831
FIB–C3 0.89 0.843–0.941
ABC3D 0.88 0.822–0.929
p value <0.0001
AAR 0.66 0.599–0.725
APRI 0.75 0.686–0.805
BARD 0.69 0.624–0.749
FIB4 0.76 0.707–0.819
NFS 0.76 0.701–0.818
ADAPT 0.85 0.803–0.896
PRO–C3 0.78 0.727–0.838
FIB–C3 0.83 0.777–0.880
ABC3D 0.81 0.755–0.856
p value <0.0001
*Prevalence advanced fibrosis *combined cohort = 0.37 *Discovery cohort = 0.40 * Validat
*DeLong DeLong Clarke test for comparison of AUROC
JHEP Reports 2019Diabetes = present. Optimal thresholds for each variable were
selected by maximising the Youden index for the corresponding
ROC curves. The presence of each factor scored 1 point, except
for T2DM which, with an OR of 5, was awarded 2 points to yield
a maximum score of 6. In the discovery cohort, the AUROC for
ABC3D was 0.88 (95% CI 0.822–0.929, p <0.001).
Validation of FIBC3 and ABC3Dmodel accuracy and derivation
of diagnostic thresholds for advanced fibrosis
The diagnostic accuracy of these models for the detection of
advanced fibrosis was confirmed in a the validation cohort (n =
298) and also in the overall combined cohort (n = 449). Diagnostic
accuracy was assessed by the standard AUROC and also the
weighted AUROC computed using the Obuchowski measure to
account for spectrum effect and ordinal scale.F3–F4 and weighted AUROC derived from the Obuchowski measure.
Combined cohort (n = 449)
Adj
AUROC
SD 95% CI
0.62 0.019 0.581–0.653
0.68 0.017 0.652–0.717
0.67 0.017 0.642–0.707
0.70 0.015 0.671–0.731
0.72 0.015 0.694–0.752
0.77 0.014 0.739–0.794
0.69 0.017 0.660–0.726
0.77 0.013 0.745–0.797
0.76 0.013 0.730–0.783
Discovery cohort (n = 151)
0.62 0.031 0.555–0.675
0.69 0.028 0.638–0.748
0.69 0.028 0.637–0.746
0.70 0.026 0.651–0.751
0.71 0.023 0.669–0.758
0.74 0.025 0.695–0.793
0.68 0.031 0.617–0.740
0.75 0.021 0.707–0.789
0.75 0.022 0.704–0.790
Validation cohort (n = 298)
0.62 0.024 0.571–0.663
0.68 0.021 0.640–0.722
0.66 0.021 0.623–0.705
0.70 0.019 0.644–0.739
0.73 0.019 0.692–0.766
0.78 0.017 0.749–0.815
0.70 0.020 0.622–0.741
0.79 0.017 0.753–0.819
0.76 0.017 0.730–0.795
ion cohort = 0.36
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Table 4. Optimal cut-off values for the detection of advanced fibrosis (≥F3) as per Youden index derived in discovery cohort (prevalence 0.40, n = 151) and
applied in validation cohort (prevalence 0.36, n = 298).
Panel AUC Cut-off Sensitivity
(%)
Specificity
(%)
PPV (%) NPV (%) Accuracy (%)
FIB-C3 0.89 >–0.4 83 80 74 88 81
ABC3D 0.88 >3 77 82 74 84 80
Validation cohort
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
AAR >0.8 46 71 47 70 62
APRI >1.5 11 96 63 66 66
BARD >2 76 51 47 79 60
FIB4 >2.67 21 94 67 68 68
NFS >0.676 27 95 78 70 71
ADAPT >6.3 76 75 63 86 76
FIB–C3 >–0.4 75 75 62 84 75
ABC3D >3 66 75 61 80 73
PPV, positive predictive value; NPV, negative predictive value.For FIBC3, the AUROC remained high in both the validation
cohort (0.83, 95% CI 0.777-0.880) and the combined cohort (0.85,
95% CI 0.812-0.886). The weighted AUROC was calculated to be
0.77, 0.75 and 0.79 in the combined, discovery and validation
cohorts, respectively. Similar results were obtained for ABC3D
with AUROC of 0.81 and 0.83 in the validation and combined
cohorts, respectivelY (Table 3). Reduced bias estimates of predicted
probability were calculated in the discovery and validation cohorts,
employing the leave-one-out method of cross-validation as pre-
viously described. To assess the added value of including PRO-C3
in the diagnostic model, we removed PRO-C3 from the FIBC3
model. This yeildedAUROCs of (0.80, 0.86 and 0.76) in the total, dis-
covery and validation cohorts, respectively. These improved to
(0.85, 0.89 and 0.83) with the inclusion of PRO-C3 in the model.
An optimal FIBC3 threshold value of >-0.4 was chosen using
the Youden index (sensitivity 83%, specificity 80%, positive predic-
tive value [PPV] 74% and negative predictive value [NPV] 88%). An
optimal ABC3D cut-off level for the detection of advanced fibrosis
was >3. In the validation cohort (n = 298), FIBC3 exhibited a sensi-
tivity of 75%, specificity of 75%, accuracy of 75% (Table 4). In the
discovery cohort, ABC3D exhibited a sensitivity of 77%, specificityTable 5. Validation cohort divided into mild and severe fibrosis (prevalence 0.3
F0–2
‘Rule out’ advanced fibrosis
Correctly
identified
Indeterminate Incorrectly
identified
N = 191 n/N (%) n/N (%) n/N (%)
AAR <0.8 135/191 (71) 56/191 (29)
APRI <0.5 112/191 (59) 72/191 (38) 7/191 (3)
BARD <2 98/191 (51) 93/191 (49)
FIB4 <1.3 133/191 (70) 47/191 (25) 8/188 (5)
NFS <–1.433 120/191 (64) 63/191 (33) 5/191 (3)
ADAPT <6.3 144/191 (75) 47/191 (25)
FIBC3 <–0.4 144/191 (75) 47/191 (25)
ABC3D <3 144/191 (75) 47/191 (25)
JHEP Reports 2019of 82%, and accuracy of 80%. This was replicated in the validation
cohort, where a sensitivity of 66%, specificity of 75% and accuracy
of 73% were observed.
Both FIBC3 and ABC3D performance were superior to simple
non-invasive scores in common use, with accuracies of 75% and
73%, respectively. Performance characteristics of FIBC3 and the
simplified ABC3D score were comparable to the recently
described ADAPT score (Table 4). Comparing AUROCs using the
DeLong, DeLong and Clarke-Pearson method confirmed that
FIBC3 and ABC3D have similar performance characteristics (p =
0.1422) as do FIBC3 and ADAPT (p = 0.1859). Using the FIBC3
model, the optimal threshold correctly staged 224 out of 298
patients (75%) in the validation cohort, compared to 227 patients
(76%) with ADAPT and 217 (73%) with ABC3D. Considering NPV,
of 191 patients with mild fibrosis, 144 (75%) were staged cor-
rectly using FIBC3 or ABC3D, equal to ADAPT (75%) (Table 5). In
the combined cohort (n = 449), 347 of the patients (77%) were
correctly staged using FIBC3, which outperformed both FIB4 at
304 (68%) and ADAPT at 341 (76%). The most simple model,
ABC3D, had a diagnostic accuracy of 75% correctly classifying
338 cases into mild or severe fibrosis.9, n = 298).
F3–4
‘Rule in’ advanced in severe
Correctly
identified
Indeterminate Incorrectly
identified
N = 107 n/N (%) n/N (%) n/N (%)
AAR >0.8 49/107 (46) 58/107 (54)
APRI >1.5 12/107 (11) 72/107 (67) 23/107 (22)
BARD >2 81/107 (76) 26/107 (24)
FIB4 >2.67 22/107 (20) 53/107 (50) 32/107 (30)
NFS >0.676 29/107 (27) 51/107 (48) 27/107 (25)
ADAPT >6.3 83/107 (78) 24/107 (22)
FIBC3 >–0.4 80/107 (75) 27/107 (25)
ABC3D >3 73/107 (68) 34/107 (32)
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We assessed the performance of FIBC3 and ABC3D in a range of
pre-test probability scenarios that may be encountered across
primary care and specialist care environments, where the preva-
lence of advanced fibrosis varies, to see if they were equivalent.
The PPV and NPV were calculated across an advanced and mild
fibrosis prevalence range between 5–50% (Table 6). We also stra-
tified our validation cohort in different, clinically distinct, sub-
populations and observed that performance was maintained
across all sub-populations, with a reliable NPV for advanced
fibrosis >74% (Table S4,5).
Performance of PRO-C3, FIBC3 and ABC3D as pre-screening
tools prior to liver biopsy to support clinical trial recruitment
As there is also a need for tools to assist in pre-screening patients for
clinical trials in NASH, we modelled the performance of PRO-C3 as
pre-screening tools for entry into clinical trials of fibrosing steatohe-
patitis. Two target populations were modelled: (i) “tdNASH”,
defined as NAS ≥4 with at least 1 point each for steatosis, hepato-
cyte ballooning and hepatic inflammation and fibrosis stage ≥F2;
and (ii) “tdNASH-Cirrhosis”, defined as above but with fibrosis
stage F4. For tdNASH, a PRO-C3 level >14.5 ng/ml had an AUROC
of 0.68 (sensitivity 59%, specificity 69%, accuracy 64%). This was
replicated in the validation cohort (n = 298), AUROC = 0.76,Table 6. Predictive values of cut-offs at different prevalences of advanced and
Combined Coh
Predictive values of cut-offs for d
FIBC3 >–0.4 ABC3D >3
Prevalence of significant fibrosis (%) PPV (%) NPV (%) PPV (%) NP
5 15 99 15
10 27 97 26
15 37 95 36
20 46 93 45
25 53 91 52
30 59 89 58
35 65 87 63
40 69 84 68
45 74 81 73
50 77 78 76
Predictive values of cut
FIBC3 <–0.4 ABC3D <3
Prevalence of mild fibrosis (%) PPV (%) NPV (%) PPV (%) NP
5 25 99 12
10 42 97 23
15 53 96 32
20 62 94 40
25 68 92 47
30 73 90 53
35 78 88 59
40 81 85 64
45 84 82 69
50 87 79 73
PPV, positive predictive value; NPV, negative predictive value.
JHEP Reports 2019sensitivity 70%, specificity 68%, accuracy 69%. Similarly, a PRO-C3
level >16.5 ng/ml identified tdNASH-Cirrhosis with an AUROC of
0.68 (sensitivity 74%, specificity 67%, accuracy 68%). This was repli-
cated in the validation cohort (n = 298), AUROC = 0.76, sensitivity
76%, specificity 61%, accuracy 63% (Table S2). The results for the
FIBC3 and ABC3D scores in the complete cohort (n = 449) are
shown in Table S6. In general, tests incorporating PRO-C3 per-
formed well. The most accurate test for the detection of tdNASH
was FIBC3 >-0.4 (71%). Phase II/III clinical trials that are currently
recruiting will be informative for the further validation of these
findings.
ABC3D to improve the accuracy of NFS and FIB4 scores
Although FIB4 and NFS are useful, the use of 2 cut-off thresholds
leads to indeterminate results that fail to classify a substantial
proportion of patients. For each diagnostic test we employed a
method of sequential testing by applying the low and high cut-
off values. The residual cohort of patients with NAFLD and inde-
terminate scores were then assessed with the ABC3D diagnostic
algorithm to detect cases of advanced fibrosis (Tables S7,8).
With the application of sequential testing, the accuracy improved
from 52% to 70% in the cases involving indeterminate FIB4 scores
and from 54% to 77% in the case involving indeterminate NFS
scores.mild fibrosis.
ort (n = 449)
ifferent prevalences of advanced fibrosis (F>3); “Rule in” advanced fibrosis
FIB4 >2.67 NFS >0.676 ADAPT >6.3
V (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
98 19 96 22 96 14 98
96 33 92 38 92 26 96
94 44 87 49 88 36 94
91 52 83 57 84 45 92
89 59 79 64 80 52 90
86 65 74 70 75 58 87
83 70 69 74 71 63 85
80 75 65 78 66 68 82
77 78 60 82 61 72 78
73 81 55 84 57 76 75
-offs for different prevalences of mild fibrosis (F<2); “Rule in” mild fibrosis
FIB4 <1.3 NFS <–1.433 ADAPT <6.3
V (%) PPV (%) NPV (%) PPV (%) NPV (%) PPV (%) NPV (%)
98 11 98 14 98 12 97
97 21 95 26 95 22 94
95 30 93 36 92 31 91
93 38 90 45 90 39 88
91 46 87 51 87 46 85
88 51 84 57 84 52 81
86 57 81 63 80 58 78
83 62 78 68 76 63 74
80 67 74 72 73 68 70
76 71 69 76 68 72 65
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Discussion
NAFLD has an estimated global prevalence of 25%, which is pre-
dicted to rise internationally.41–43 Associated mortality is directly
proportional to fibrosis stage, with patients at ≥F3 being at high-
est risk.2 Current non-invasive tests are suboptimal; therefore,
there is a clear need for better diagnostic biomarkers to detect
advanced fibrosis. Such tests could potentially aid diagnosis and
risk stratification, as well as facilitate clinical trial pre-screening
to reduce screening failure rates; all of which fall within the
BEST diagnostic context of use.11
At present, the reference standard to assess severity of NAFLD is
histological, using the semi-quantitative NASH CRN system.37
However, it is generally accepted that inter- and intra-observer
variability, and sampling error due to variability in the extent
of fibrosiswithin the liver,may impair the accuracy and reproduci-
bility of these histological assessments.37,44,45 This implies a
paradox that makes addressing the need for biomarkers all the
more challenging: the histological reference standard, against
which a biomarker is assessed, is inherently imperfect and unable
to produce a completely error-free classification with respect to
the presence or absence, or severity, of the target condition.
Semi-quantitative histological grading conflates anatomical distri-
bution of fibrosis with extent and imposes discrete categorical
staging bins onwhat are continuous variables like collagen deposi-
tion.37 This inevitably leads to discrepancies due to inter- and
intra-observer judgement, especially at the margins. It also blunts
sensitivity as semi-quantitative grades fail to recognisemodest dif-
ferences in severity that do not transition across predefined but
arbitrary categorical boundaries. This phenomenon is well illu-
strated by the breadth of disease that is encompassed by stage F3
fibrosis in the NASH CRN classification37 where histological
portal-portal, central-central and/or portal-central bridging is the
defining feature, yet no weight is given to density of collagen
deposition or the number of “bridging” septae. The situation
where an imperfect reference standard is used in place of a perfect
standard, introduces “imperfect gold standard bias”. This means
that the performance of the new test may be under- or over-
estimated and, even if it is in reality a better measure of disease,
it never has the potential to generate an AUROC >0.90.46 Although
not unique to liver histopathology, such situations are methodolo-
gically challenging to address.47
Cognisant of these challenges, we report measurement of
PRO-C3 levels in a large international cohort and incorporate
this measure into novel diagnostic models that outperform
numerous previously described blood-based tests that detect
advanced fibrosis.12–18
Utility of PRO-C3 as a single diagnostic biomarker
Although isolated parameters seldom exhibit an adequate level of
diagnostic accuracy and are unlikely to be a surrogate for the com-
plex diagnostic information provided by liver biopsy, we assessed
how PRO-C3 performed in this context of use. PRO-C3 performed
moderately as a biomarker of advanced fibrosis, comparable to
simple panels such as FIB4. Similarly, when used to screen
patients for clinical trial recruitment, PRO-C3 accurately identified
65% of cases that were histologically eligible for current phase III
trial recruitment (NASH with significant fibrosis). This moderate
performance as a diagnostic biomarkermay partially be explained
by the biological process that generate PRO-C3 during collagen
deposition, implying that PRO-C3 is most sensitive to active fibro-
genesis rather than static collagen accumulation. Supporting thisJHEP Reports 2019view, preliminary evidence suggests that PRO-C3may aid the eva-
luation of patients with active collagen turnover.48 In the present
study wewere unable to assess the value of PRO-C3 as a prognos-
tic test, that could be used to enrich studies for cases at greatest
risk of subsequent disease progression, or to monitor change in
disease severity.
FIBC3 and ABC3D performance for risk stratification of
fibrosing steatohepatitis
In light of the moderate performance of PRO-C3 as a single
diagnostic biomarker, we assessed its value as part of a non-
invasive fibrosis panel composed of routinely measured clinical
and laboratory variables enhanced by inclusion of a single bio-
marker of fibrogenesis, PRO-C3. We report development and
validation of FIBC3. Whilst not the first panel to incorporate
these components, many of which are used within ADAPT,29
the current study benefits from detailed development and vali-
dation in a large, international patient cohort where careful
harmonisation of histological practice, coupled with central
reviewing of biopsies, has been undertaken to minimise the
potential impact of an imperfect reference standard. Overall, a
FIBC3 threshold of >-0.4 correctly identified fibrosis status in
77% of patients in the total cohort. However, the diagnostic
accuracy of ABC3D, a simplified panel, better adapted for use
in clinical practice (at the bedside) rivalled this model with an
accuracy of 75% and performed equivalently when assessed
across different clinical sub-populations and consistently out-
performed all other routinely used scores to which it has been
compared. Thus, in contrast to FIB4, NFS or the PRO-C3 based
ADAPT score, which require more complex formulas, this simple
model can be easily calculated by summing 5 easy to assess clini-
cal items, removing the need to access to a web-based calculator
or App to aid patient risk stratification. Furthermore, in contrast
to FIB4 or NFS, FIBC3 and ABC3D both have a single, optimised,
risk-threshold value, without “indeterminate” results which
would require further testing or liver biopsy to clarify disease
severity.19
In the validation cohort, FIBC3 performed best, correctly iden-
tifying 75% of patients, with ABC3D more or less equivalent
correctly identifying 72% of patients. In the full cohort of 449
patients, the FIBC3 model identified 254 patients as not having
advanced fibrosis (at a threshold of less than -0.4) of which 217
were correctly classified. Therefore, in this “low-risk cohort” the
FIBC3 model could have correctly avoided a liver biopsy in 85%
of patients. Applying the same analysis to ABC3D, 267 patients
were identified as ‘low-risk’ (score ≤3). In this cohort, 219 patients
were correctly staged, thus potentially correctly avoiding biopsies
in 82% of cases. Complex fibrosis panels also exist. They include
markers of matrix turnover, such as the Enhanced Liver Fibrosis
(ELF™) panel.18 However, a recent meta-analysis has reported
that ELF and NFS have very similar AUCs.49 Extrapolating this
observation to our data would imply that FIBC3/ABC3D (like the
NFS) had comparable, if not better, diagnostic value than the
more complex Fibrotest and ELF.
Potential to use ABC3D in primary care
The point performance of diagnostic tests in terms of PPV/NPV
are affected by pre-test probability, which reflects the preva-
lence of disease in a specific clinical setting. The prevalence of
advanced fibrosis in the current study cohort was 37% which
is much higher than would be expected in a primary care set-
ting. Indeed, population data, albeit limited, have found thatvol. 1 | 188–198 195
Research Article5.6% of the Dutch population have clinically significant fibrosis
based on a VCTE liver stiffness >8 kPa.50 Similarly, based on
VCTE thresholds ≥6.8, ≥8.0, and ≥9.0 kPa prevalence estimates in
the Spanish population were 9.0%, 5.8%, and 3.6%, respectively.51
These levels contrast sharply to a tertiary referral centre where
the prevalence of advanced liver disease is often well in excess
of 10%, and frequently nearer 30%.52–54 To model performance
across a range of settings, we calculated PPV and NPV for preva-
lence levels of advanced fibrosis from 5–50%. The NPV for both
FIBC3 and ABC3D were similar across a prevalence range of
5–15% and in excess of 90%. To explore performance of themodels
in specific patient subgroups, we split the cohort by gender, dia-
betes status, BMI, and patients with elevated or normal alanine
aminotransferase levels. FIBC3 and ABC3D maintained high NPV
in all subgroups, although sensitivity was lower in patients with
a BMI <25 and non-diabetics.
Strengths and limitations
FIBC3 and ABC3D were developed using an international cohort
of well-characterised, untreated patients with NAFLD, covering
a wide spectrum of disease severity. Liver biopsies were read by
expert histopathologists that belong to the EPoS consortium
pathology group, a group that undertook extensive harmonisa-
tion procedures for NAFLD pathological assessment and demon-
strated high kappa-value reproducibility.45 Moreover, half of the
biopsies across all sites were assessed centrally. While this
certainly reduces the reader-related variability, it is still depen-
dent on limitations intrinsic to histological classifications such
as the semi-quantitative nature of fibrosis scoring and on sam-
pling variability of the procedure. These limitations are common
to all biomarkers that use biopsy as the reference standard. Our
diagnostic model consists of readily available clinical and labora-
tory variables that are routinely determined in patients with
NAFLD in outpatient appointments. PRO-C3 levels were also mea-
sured in a central College of American Pathologists certified lab
by staff blinded to the clinical data, before results were sent to a
separate, independent centre for statistical analysis. Protein
finger print technology has been developed to produce a reliableJHEP Reports 2019assay for PRO-C3 measurement.25 Our model, in comparison to
previous complex biomarker panels (e.g. ELF or Fibrotest)
includes only one variable that is not routinely measured in
a clinical setting. To minimise the effects of inter-observer varia-
bility in fibrosis staging, half the cohort across all centres had
centrally reviewed liver biopsies confirming high inter-observer
agreement.
Although we have taken measures to minimise inter-observer
variability in the histological scoring, and concordance between
liver pathologists was very good, an element of variability cannot
be fully excluded. We also acknowledge that percutaneous
liver biopsy is prone to sampling error leading to mis-staging
of disease severity. However, the key limitation, which is com-
mon to all biomarker studies that rely on histology, relates to
the nature of the semi-quantitative scoring systems and how
this conflates histological localisation of fibrosis and extent of
collagen deposition. We also acknowledge that AUROCs are
not perfect as a means for assessing diagnostic accuracy. ROC
curves attribute equal weight to false positives and false nega-
tives and do not provide information on predictive values,
which may be of greater value in a clinical setting.55 Our results
require further independent validation in other patient popula-
tions, to critically assess these models’ ability to discriminate
fibrosis stage.
In conclusion, both FIBC3 and ABC3D are simple indices
including accessible routine laboratory tests and a single marker
of collagen turnover. We have shown that both can accurately
differentiate mild to moderate fibrosis from bridging fibrosis
and cirrhosis in patients with NAFLD. Given that the ABC3D
model is much simpler to compute and can be done at the bed-
side, the ABC3D diagnostic index has the potential to be widely
used for the identification of patients with significant/active
fibrosing steatohepatitis who should undergo specialised liver
explorations, closer monitoring and possibly, specific therapies.
FIBC3 and ABC3D may also be used as pre-screening tools for
therapeutic trials, potentially helping to minimise histological
severity-related screening failure rates. However, this will require
further prospective validation.Financial support
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